100 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
29 Feb 24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7:35am
products or clinical trials, please contact the Medical Information department at:
Tel: +1 (888) 209-9326,
Email: medicalinformation@karyopharm.com
8-K
KPTI
Karyopharm Therapeutics Inc
20 Feb 24
Other Events
8:00am
a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance
8-K
EX-99.1
hvxdtinp44xjkcq
8 Jan 24
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
8:40am
8-K
8yx 68d5vsh4xq2xxi
12 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
EX-99.1
7x17 4lxtxlu
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
osd22 oakhd6
2 Aug 23
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
9xu6mtb0y5xkbg
4 May 23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:53am
8-K
EX-10.1
c97qaf5n 3v6x5qi32pp
5 Dec 22
Karyopharm Announces $165 Million Private Placement
8:41am